AzurRx doses first patients in Phase II OPTION study for EPI therapy
Category: #health  By Mateen Dalal  Date: 2019-02-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

AzurRx doses first patients in Phase II OPTION study for EPI therapy

AzurRx BioPharma, Inc. has recently informed that the company has dosed the first patients in its Phase II OPTION clinical study aimed at investigating MS1819-SD in cystic fibrosis (CF) patients who experience exocrine pancreatic insufficiency (EPI).

Supposedly, the multi-center Phase II trial has been designed to explore the efficacy, tolerability and safety of MS1819-SD, comparing it directly with the existing porcine enzyme replacement therapy (PERT) care standard. Around 30 CF patients are planned to be enrolled in the study, with top-line results being expected in mid-2019.

According to AzurRx BioPharma, the OPTION study primarily involves a six week long non-inferiority and coefficient of fat absorption (CFA) evaluation to compare MS1819-SD with the standard of care PERT in patients with EPI resulting from cystic fibrosis. Its cross-over study design would be able to leverage input from the CF community as well as from the U.S. Food and Drug Administration. The nearly 30 patients to be enrolled in the trial would be aged 18 years or above, the company stated.

Michael W. Konstan, M.D., Case Western Reserve University School of Medicine’s Professor of Population & Quantitative Health Sciences as well as Pediatrics, who is also the Vice Dean for its Translational Research, mentioned that for a long time the CF community has identified the unmet need regarding a non-porcine based pancreatic enzyme option, as an alternative to current treatments of EPI in CF patients.

The company said that in a recently confirmed Phase II trial in the chronic pancreatitis setting, a good tolerability and favorable safety profile was exhibited by MS1819-SD. Besides, the highest studied dose had shown a statistically significant improvement in CFA of 21.8%.

AzurRx’s CEO, Thijs Spoor commented that dosing the first patients in the company’s OPTION trial of MS1819-SD in CF patients is representative of the firm’s remarkable achievement, demonstrating that it is on track to finish the Phase 2 study by mid-2019, the previously informed timeline.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
SpringWorks begins Phase 3 trial of desmoid tumor treatment in adults
By Mateen Dalal

The company is looking forward to enrolling patients with desmoid tumors to confirm the clinical benefits of nirogacestat SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, has reportedly announced the beginning of Phase 3 “...

Exelixis & Iconic Therapeutics ink exclusive license and option deal
Exelixis & Iconic Therapeutics ink exclusive license and option deal
By Mateen Dalal

The exclusive license & option agreement has been signed for a new Antibody-Drug conjugate program.   The program, named ICON-2, specifically targets Tissue Factor and would have a potential broad impact on oncology. Exelixis, Inc., (E...

JD.com invests $55 million to foster connected vehicle fleets
JD.com invests $55 million to foster connected vehicle fleets
By Mateen Dalal

The launch of logistic service has begun to reap early rewards regarding cost saving. The long-time rival of Alibaba and Amazon, JD.com, has reportedly announced to invest 376 million yuan (around $55 million) in Jiangsu Xinning Modern Logistics to ...